T2DM Management Priorities: Time to Align
Aug 4, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Louise Brown, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Advances in diabetes technology and treatment over the past decade have failed to yield desired glycemic outcomes in many patients with T2DM.
A recently published study evaluated if a disconnect between patients' and physicians' beliefs and perceptions about diabetes management could be contributing to suboptimal glycemic outcomes.
Studies have shown that only 30 percent of patients with T2DM treated with basal insulin achieved an A1C< 7.0 percent. The likelihood of reaching this A1C target is reduced if not achieved within one year of starting insulin.1 In patients unable to achieve A1C goals on oral medications, an injectable such as basal insulin is recommended, and the dose is titrated up or down to reach desired glycemic outcomes....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.